Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Balanced, 4-Way, Incomplete Block Design to Evaluate the Effects of a Single Administration of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG (qEEG) in Healthy Subjects

NCT00519298 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00519298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00519298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Balanced, 4-Way, Incomplete Block Design to Evaluate the Effects of a Single Administration of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG (qEEG) in Healthy Subjects
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
March 31, 2008
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult, healthy